证券代码：002622 证券简称：皓宸医疗 公告编号：2025-029 皓宸医疗科技股份有限公司 关于控股孙公司收到法院传票及《民事裁定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：收到传票，尚未开庭审理。 2、上市公司所处的当事人地位：皓宸医疗科技股份有限公司（以下简称"公司"）、 全资子公司植钰医疗投资有限公司（以下简称"植钰医疗"）及其控股子公司广东德伦医 疗集团有限公司（以下简称"德伦医疗"）为被告。 3、涉案的金额：植钰医疗持有的德伦医疗股权，持股比例为 51%，对应出资额为 2,652 万元。 4、对上市公司损益产生的影响：本次诉讼所涉及为债权人转让撤销权纠纷，其判决 结果预计不会对公司本期利润或期后利润造成直接影响。若法院对该案采取进一步措施， 则可能存在被司法处置的风险，可能对公司及子公司的生产经营产生一定的影响。 公司于 2025 年 10 月 30 日收到控股孙公司德伦医疗转发的吉林市船营区人民 法院出具的案号（2025）吉 0204 民初 4757 号《传票》《民事裁定书》《民事起诉 状》 ...

Core Viewpoint - Haocen Medical, established in 1998 and listed in 2011, operates in the medical services sector with a focus on oral healthcare, but its financial performance lags behind industry leaders [1][2]. Financial Performance - For Q3 2025, Haocen Medical reported revenue of 527 million yuan, ranking 14th in the industry, significantly lower than the top player Aier Eye Hospital's 17.48 billion yuan and second-place Meinian Health's 6.93 billion yuan [2]. - The company's main revenue source is oral medical services, generating 288 million yuan, accounting for 91.98% of total revenue, while industrial switch products contributed 24.11 million yuan (7.69%) and other income was 1.04 million yuan (0.33%) [2]. - The net profit for the same period was -31.03 million yuan, placing it 13th in the industry, far behind Aier Eye Hospital's 3.367 billion yuan and Tongce Medical's 616 million yuan [2]. Financial Ratios - As of Q3 2025, Haocen Medical's debt-to-asset ratio was 71.72%, up from 68.55% year-on-year and above the industry average of 46.74% [3]. - The gross profit margin stood at 47.72%, slightly down from 47.97% year-on-year but still above the industry average of 31.10% [3]. Management and Shareholder Information - The chairman, Lu Lu, has a salary of 1.2 million yuan for 2024, unchanged from 2023 [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 4.97% to 46,200, while the average number of shares held per shareholder increased by 5.23% to 18,200 [5].

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-027 经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于 2025 年第三季度报告的议案》 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案已经公司审计委员会审议并取得了明确同意的意见。 皓宸医疗科技股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 10 月 30 日上午 10:00 在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2025 年 10 月 19 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 1、《皓宸医疗科技股份有限公司第五届董事会第十六次会议决议》。 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二五年十月三十日 《2025 ...

Core Insights - Haocen Medical reported a decline in revenue and an increase in net loss for the third quarter and the first three quarters of the year [1] Financial Performance - In Q3, the company achieved operating revenue of 213.26 million yuan, a year-on-year decrease of 15.72% [1] - The net loss attributable to shareholders for Q3 was 2.66 million yuan, a year-on-year decrease of 120.54% [1] - For the first three quarters, the company reported operating revenue of 526.89 million yuan, a year-on-year decrease of 17.03% [1] - The net loss attributable to shareholders for the first three quarters was 26.41 million yuan, a year-on-year decrease of 295.68% [1]

Core Viewpoint - Haocen Medical (002622.SZ) reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 527 million yuan, representing a year-on-year decrease of 17.03% [1] - The net profit attributable to shareholders was -26.41 million yuan, indicating a loss [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -24.52 million yuan [1] - The basic earnings per share were -0.0314 yuan [1]

Group 1 - The core point of the article is that Haocen Medical (SZ 002622) held its 16th meeting of the 5th Board of Directors on October 30, 2025, to review the proposal for the Q3 2025 report [1] - For the first half of 2025, Haocen Medical's revenue composition is as follows: 91.98% from the dental industry, 7.69% from switches, and 0.33% from leasing [1] - As of the report date, Haocen Medical has a market capitalization of 2.7 billion yuan [1]

Group 1 - The core point of the article is that Haocen Medical reported a significant decline in revenue and incurred a net loss in the third quarter of 2025 [1] - For the first three quarters of 2025, the company's revenue was approximately 527 million yuan, representing a year-on-year decrease of 17.03% [1] - The net profit attributable to shareholders was a loss of approximately 26.41 million yuan, with basic earnings per share reflecting a loss of 0.0314 yuan [1] Group 2 - As of the report, Haocen Medical's market capitalization stands at 2.7 billion yuan [2]

Financial Performance - The company's operating revenue for Q3 2025 was ¥213,255,740.57, a decrease of 15.72% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,658,745.89, representing a decline of 120.54% year-on-year[5] - The basic earnings per share were -¥0.0031, down 120.13% from the previous year[5] - Total operating revenue decreased to ¥526,891,688.79 from ¥635,030,298.87, representing a decline of approximately 17.1% year-over-year[30] - Net profit for the period was a loss of ¥31,025,238.07 compared to a profit of ¥28,681,678.30 in the previous period, indicating a substantial decline[31] - Total comprehensive income for the period was -¥38,291,121.64, a significant drop from ¥30,221,773.21 in the prior year[32] - The company experienced a total loss of ¥28,257,351.48 in profit before tax, compared to a profit of ¥31,302,613.93 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,453,688,194.93, a decrease of 2.92% from the end of the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 1,042,562,022.36, down from CNY 1,054,436,349.33, indicating a reduction of about 1.1%[29] - The company's cash and cash equivalents decreased to CNY 125,287,409.13 from CNY 147,693,180.87, representing a decline of approximately 15.2%[27] - Accounts receivable fell to CNY 27,073,537.72 from CNY 39,169,433.88, a decrease of about 30.9%[27] - Inventory increased to CNY 57,657,756.69 from CNY 50,753,348.55, marking an increase of approximately 13.5%[27] - The company's total equity decreased to CNY 411,126,172.57 from CNY 443,047,294.21, reflecting a decline of about 7.2%[29] Research and Development - Research and development expenses increased by ¥606,000, or 108.60%, compared to the same period last year[9] - Research and development expenses increased significantly to ¥11,646,500.56 from ¥5,583,042.65, marking a rise of approximately 108.5% year-over-year[31] Cash Flow - The company reported a net cash flow from operating activities of -¥10,146,191.88, a decrease of 123.56% year-to-date[5] - The net cash flow from operating activities was negative at -¥10,146,191.88, a decrease from a positive cash flow of ¥43,066,291.87 in the prior year[34] - Cash and cash equivalents at the end of the period stood at ¥110,286,409.13, down from ¥152,382,007.24, reflecting a decrease of approximately 27.6%[34] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings and updates related to the Jin Haitang case, with various court documents filed from 2020 to 2024[15] - The company has reported that it is in communication with the executing party and the Shanghai Financial Court regarding the Jin Haitang asset management case[16] - The company has faced asset freezes due to disputes with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank Co., Ltd.[21] - The company has not yet fulfilled its repayment obligations to Zhejiang Zheshang Asset Management Co., Ltd. and is exploring solutions to address its debt issues[21] - The company has disclosed that it has received a debt transfer notification from Zhejiang Zheshang Asset Management Co., Ltd. to Zhejiang Zheba Xianv Lake Enterprise Management Partnership[19] - The company has reported on the freezing of bank accounts and assets of its subsidiaries, with updates provided on various dates in 2023[18] Shareholder and Equity Changes - The total equity attributable to shareholders was ¥364,359,479.58, down 8.46% from the end of the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 46,198[12] - The first major shareholder, 汇垠日丰, has become the sole trustee of a specific asset management plan, indicating a shift in control dynamics[23] - The company is actively preparing a detailed equity change report following recent court rulings affecting its control structure[24] - The company is actively seeking to negotiate with creditors regarding debt relief, extension, installment repayment, and financing replacement options[21] Investor Advisory - The company reminds investors to be aware of investment risks and to invest rationally[17] - Investors are advised to remain cautious and rational in their investment decisions due to ongoing uncertainties surrounding the company's control and financial performance[25]

Core Points - The company held its first extraordinary general meeting of shareholders in 2025, which was conducted legally and effectively [4][5][25] - The meeting involved a combination of on-site and online voting, with a total of 255 shareholders participating, representing 205,608,100 shares, or 24.4772% of the total voting shares [5][6][7] Meeting Details - The meeting took place on October 16, 2025, at 14:45 in Beijing [4] - The meeting was convened by the board of directors and chaired by the company's chairwoman, Ms. Lu Lu [4][9] Voting Participation - A total of 255 shareholders participated, with 3 attending in person and 252 voting online [5][6][7] - Among the participating shareholders, 251 were small investors, representing 5,575,100 shares, or 0.6637% of the total voting shares [8] Resolutions and Voting Results - The meeting approved several resolutions, including amendments to the company's articles of association, with 99.6450% of votes in favor [10][11] - Other resolutions, such as the rules for shareholder meetings and board meetings, also received overwhelming support, with approval rates exceeding 99% [12][14][19][21] Legal Compliance - The legal opinions provided by the law firm confirmed that the meeting's procedures complied with Chinese laws and regulations, ensuring the legitimacy of the voting process and results [25][26]

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于皓宸医疗科技股份有限公司 2025年第一次临时股东大会的法律意见书 致：皓宸医疗科技股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受皓宸医疗科技股份有 限公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 10 月 16 日下午 14:45 在北京市朝阳区光华路 5 号院世纪财富中心东亚银行大厦 18 层 1810 室召开的公司 2025 年第一次临时股东大会（以下简称"本次股东大会"）， 并依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》等中国现行法律、法规和其他规范性文件（以下简称"中国法律法规"） 及《皓宸医疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本次股东大会的召集和召开程序、出席会议人员资格、召集人资格、会议表决 程序和表决结果等事宜（以下简称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司 ...